Lumendi Ltd.

Lumendi Ltd., is focused on the development of new minimal invasive surgical tools and devices that will provide solutions for minimally invasive gastrointestinal surgeries. The company’s first product is an add-on to any commercially available endoscope that will avoid invasive colon resections to treat more complex gastrointestinal diseases.

Hemogenyx Therapeutics, Inc.

Hemogenyx Therapeutics is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (“BM”) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells.

Embark Veterinary, Inc.

Embark is a veterinary science-focused company specializing in canine genetics. Through the use of cutting-edge genetic testing and analysis, Embark offers 21st century pet wellness advice coupled with comprehensive ancestry, morphological trait, and genetic disease information for dog owners.

Conamix, Inc.

Conamix is commercializing high performance battery materials based on proprietary Cornell technology. The company’s unique battery materials allow higher energy density in existing lithium ion architectures and are manufactured using low cost and highly commercial methods.

CycloPure, Inc.

CycloPure is engaged in the design, development, and commercialization of a new class of highly adsorbent materials for use in the separation and removal of pollutants, VOCs, and other organic compounds from water and air. The technology was partly developed by the Helbling Research Group at The School of Civil and Environmental Engineering. CycloPure has raised $8.81M in funding to date.

Annapurna Therapeutics Limited

Annapurna Therapeutics is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases. Annapurna’s product pipeline includes programs for alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), the cardiomyopathy associated with Friedreich’s ataxia and severe allergy. Annapurna Therapeutics was acquired by Avalanche Biotechnologies, Inc. in 2016.

XyloCor Therapeutics, Inc.

XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.

Metro Mid-Atlantic Biotech, LLC

Metro Mid-Atlantic Biotech is a development stage startup focused on developing novel small molecule therapeutics based on discoveries in the molecular mechanisms of aging and longevity in mammalian cells.

Fesarius Therapeutics, Inc.

Fesarius Therapeutics is developing engineered tissue scaffold products for the skin and dermal layers. The products are based off the patent-pending microstructure-containing gel scaffold technology developed at Cornell. The acellular skin replacement will aim to benefit those with wounds resulting from burns, plastic surgery, tumor removal, and other forms of trauma. The company joined the National Institutes of Health as part of its I-Corps @ NIH Winter 2020 Program in February 2020.

Lumidyne Technologies, LLC

Lumidyne develops next-generation fluorescent probes exhibiting superior brightness and stability compared with current commercially available reagents.